Table 1.
Main characteristics of studies included in this meta-analysis
| |
|
NUCB2 mRNA expression |
|
||
|---|---|---|---|---|---|
| Variable | Group | High | Low | Total | P value |
| Age |
|
|
|
|
0.100 |
| |
<70 |
43 (44.3%) |
54 (55.7%) |
97 |
|
| |
≥70 |
47 (56.6%) |
36 (43.4%) |
83 |
|
| Lymph node metastasis |
|
|
|
|
0.022 |
| |
Negtive |
77 (47.2%) |
86 (52.8%) |
163 |
|
| |
Positive |
13 (76.5%) |
4 (23.5%) |
17 |
|
| Surgical margin status |
|
|
|
|
0.578 |
| |
Negtive |
82 (49.4%) |
84 (50.6%) |
166 |
|
| |
Positive |
8 (57.1%) |
6 (42.9%) |
14 |
|
| Seminal vesicle invasion |
|
|
|
|
0.202 |
| |
Negtive |
67 (46.2%) |
78 (53.8%) |
145 |
|
| |
Positive |
23 (65.7%) |
12 (34.3%) |
35 |
|
| Clinical stage |
|
|
|
|
0.880 |
| |
T1 |
52 (50.5%) |
51 (49.5%) |
103 |
|
| |
T2/T3 |
38 (49.4%) |
39 (50.6%) |
77 |
|
| Preoperative PSA |
|
|
|
|
0.004 |
| |
<4 |
1 (20%) |
4 (80%) |
5 |
|
| |
4-10 |
23 (35.9) |
41 (64.1%) |
64 |
|
| |
>10 |
66 (59.5%) |
45 (40.5%) |
111 |
|
| Gleason score |
|
|
|
|
|
| |
<7 |
35 (35.4%) |
64 (64.6%) |
99 |
<0.001 |
| |
7 |
19 (55.9%) |
15 (44.1%) |
34 |
|
| |
>7 |
36 (76.6%) |
11 (23.4%) |
47 |
|
| Angiolymphatic invasion |
|
|
|
|
0.004 |
| |
Negtive |
66 (44.9%) |
81 (55.1%) |
147 |
|
| Positive | 24 (72.7%) | 9 (27.3%) | 33 | ||